Related Experiment Videos
Effects of tumor-enhancing IgG2 on macrophage function
Julius M Cruse1, Robert Lewis, Smaroula Dilioglou
1Department of Pathology, School of Medicine, University of Mississippi Medical Center, Jackson, MI 39216, USA. jcruse@pathology.umsmed.edu
Experimental and Molecular Pathology
|June 25, 2004
Summary
Tumor-enhancing IgG2 antibodies unexpectedly enhance allograft destruction by promoting macrophage-mediated cytotoxicity. This finding contrasts with typical immune responses, revealing a novel mechanism in allograft rejection involving specific antibody subclasses.
Area of Science:
- Immunology
- Transplantation Biology
- Oncology
Background:
- Macrophages (M phi) are critical effector cells in allograft rejection.
- The role of specific antibody subclasses, like tumor-enhancing IgG2, in modulating macrophage activity during transplantation is not fully understood.
- Previous studies suggest certain antibodies can protect grafts, but the function of tumor-enhancing IgG2 remains unclear in this context.
Purpose of the Study:
- To investigate the effect of tumor-enhancing (te) IgG2 alloantibody on macrophage-mediated destruction of allogeneic tumor cells.
- To determine if te IgG2 acts as a cytophilic opsonin that influences allograft rejection dynamics.
- To elucidate the mechanism by which te IgG2 impacts macrophage cytotoxicity against foreign cells.
Main Methods:
- Utilized chromium-51 ((51)Cr) release assays to quantify target tumor cell lysis by macrophages.
- Compared cytotoxicity induced by immune and non-immune macrophages from Tennessee Swiss (TS) mice against C3H(f)/He tumor cells.
- Assessed the impact of te IgG2 and non-enhancing IgG2 on macrophage-mediated tumor cell destruction.
- Demonstrated cytophilic te IgG2 binding to macrophages using target red cells and tumor cells.
- Employed electron microscopy to visualize antibody-target cell interactions and macrophage ingestion.
Main Results:
- Immune macrophages destroyed significantly more allogeneic tumor cells than non-immune macrophages.
- Tumor-enhancing IgG2 suppressed the cytotoxicity of normal macrophages but potentiated the cytotoxic activity of immune macrophages against allogeneic tumor cells.
- Evidence confirmed cytophilic binding of te IgG2 to macrophages and demonstrated enhanced tumor cell destruction mediated by these antibody-coated macrophages.
Conclusions:
- Contrary to expectations of graft protection, tumor-enhancing IgG2 alloantibody significantly facilitates macrophage-mediated allograft destruction.
- The cytophilic nature of te IgG2 enhances macrophage effector functions, leading to increased lysis of allogeneic target cells.
- These findings reveal a novel pathway where specific antibody subclasses can promote, rather than inhibit, allograft rejection via enhanced macrophage activity.